Epothilone-d rescues cognition and attenuates alzheimer’s disease-like pathology in APP/PS1 mice by Ferbandez-Valenzuela, Juan Jose et al.

July 2-6, 2016 | Copenhagen, Denmark
Organised by the Federation of European Neuroscience Societies (FENS)
Hosted by the Danish Society for Neuroscience
Where European Neuroscience 
meets the world
91298_FENS 2016_COVER.indd   2 8/06/16   11:15
POSTER 
PRESENTATION I
Sunday July 3, 2016
89POSTER PRESENTATION I – SUNDAY JULY 3, 2016 |
POSTER PRESENTATION I
SUNDAY JULY 3, 2016
BOARD NO INDEX NUMBER
SESSION TIME: 09:30 - 13:00
PRESENTATION TIME: 11:30 - 13:00 Poster Area
C012 EPOTHILONE-D RESCUES COGNITION AND ATTENUATES ALZHEIMER’S DISEASE-LIKE PATHOLOGY IN APP/PS1 MICE 301
J.J. Fernandez-Valenzuela, R. Sanchez-Varo, V. De Castro, F.J. Moyano, M.L. Vizuete, J.C. Davila, J. Vitorica, 
A. Gutierrez (Málaga, Spain)
C013 AMYLOID-PLAQUES TOXICITY INCREASES DURING THE PROGRESSION OF ALZHEIMER'S DISEASE 302
C. Nunez Diaz, E. Sanchez-Mejias, R. Sanchez-Varo, L. Trujillo-Estrada, A. Gomez-Arboledas, J.C. Davila, J. Vitorica, 
A. Gutierrez (Málaga, Spain)
C014 RECIPROCAL INFLUENCE BETWEEN APP EXPRESSION AND GLUCOSE METABOLISM IN THE HIPPOCAMPUS 303
M. Gloire, L. Ris, A. Villers (Mons, Belgium)
C015 PICOMOLAR AMYLOID-BETA MODULATES SYNAPTIC PLASTICITY BY ACTING ON THE NO/CGMP/CREB PATHWAY 304
W. Gulisano, M. Melone, S. Giunta, C. Ripoli, D. Li Puma, C. Loreto, O. Arancio, C. Grassi, F. Conti, A. Palmeri, D. Puzzo (Catania, Italy)
C016 AMYLOID-BETA PEPTIDE IS NEEDED FOR CGMP-INDUCED LONG-TERM POTENTIATION AND MEMORY 305
D. Puzzo, R. Ricciarelli, W. Gulisano, M.R. Tropea, C. Rebosio, O. Arancio, E. Fedele, A. Palmeri (Catania, Italy)
C017 SORTILINS IN CELLULAR TRAFFICKING OF APOE 306
M. Holm, S. Glerup, K. Weyer (Aarhus, Denmark)
C018 HEPARAN SULFATES ARE INVOLVED IN AMYLOIDOSIS AND NEUROINFLAMMATION IN TRANSGENIC MOUSE MODELS OF 
ALZHEIMER DISEASE 307
C. Jendresen, H. Cui, X. Zhang, I. Vlodavsky, L. Nilsson, J. Li (Oslo, Norway)
DISORDERS OF THE NERVOUS SYSTEM:  
C.2.A PARKINSON’S DISEASE - GENETIC DETERMINANTS
C019 MUTATIONS IN PARKINSON’S DISEASE COMMON GENES ARE RARE IN A POPULATION OF SAUDI PATIENTS AS 
REVEALED BY WHOLE-EXOME SEQUENCING 308
B. Al-Mubarak, E. Alyemni, D. Monies, M. Abouelhoda, S. Bohlega, T. Alkhairallah, E. Goljan, M. Al Breacan, R. Albar, 
A. Magrashi, M. AlTurki, B. AlTawil, B. Alsaffar, A. Almusaiab, S. Bin Ghadir, L. Bahour, L. Alshakmobarak,  
H. Abou Al-Shaar, M. ElKalioby, N. Al Tassan (Riyadh, Kingdom of Saudi Arabia)
C020 GENOME WIDE ASSESSMENT OF PARKINSON’S DISEASE IN A SOUTHERN SPANISH POPULATION 309
R. Duran Ogalla, S. Bandres-ciga, T.R. Price, F. Barrero, F. Escamilla-sevilla, J. Pelegrina, S. Arepalli, D. Hernandez, 
B. Gutierrez, J. Cervilla, M. Rivera, A. Rivera, J. Ding, M. Nalls, A. Singleton, F. Vives (Granada, Spain)
C021 DOMINANT NEGATIVE VARIANT OF THE DOPAMINE TRANSPORTER ASSOCIATE WITH EARLY-ONSET PARKINSONISM 
AND PSYCHIATRIC DISEASE 310
F. Hansen, T. Skjørringe, N. Arends, K. Erreger, L. Friberg, A. Galli, L. Møller, L. Hjermind, U. Gether  
(København, Denmark)
C022 NON-CODING RNAS AND THEIR REGULATION OF ALPHA-SYNUCLEIN IN VIVO IN A PARKINSON’S DISEASE MODEL 311
M. Jakobsen, T.B. Hansen, J. Jakobsson, N. Casadei, O. Riess, M. Romero-Ramos, J. Kjems (Aarhus, Denmark)
C023 IDENTIFICATION OF MULTIPLE QTLS LINKED TO NEUROPATHOLOGY IN THE ENGRAILED1 HETEROZYGOUS MOUSE MODEL 
OF PARKINSON'S DISEASE 312
M. Jewett, Z. Kurowska, P.L. Brattås, I.J. Ferrer, X. Kenez, T. Björklund, U. Nordstöm, P. Brundin, M. Swanberg (Lund, Sweden)
C024 MHCII- MEDIATED EFFECTS ON MICROGLIAL ACTIVATION AND DOPAMINERGIC NEURODEGENERATION INDUCED BY 
OVEREXPRESSION OF ALPHA-SYNUCLEIN 313
I. Jimenez Ferrer, M. Jewett, A. Tontanahal, M. Romero-Ramos, M. Swanberg (Lund, Sweden)
C025 HOW DOES THE LOSS OF FBXO7 IN MYELINATING CELLS CONTIBUTE TO PARKINSONISM? 314
S. Joseph, S. Vingil, W. Möbius, K.A. Nave, J. Stegmüller (Göttingen, Germany)
C026 VALIDATION OF CIRS-7 AS A TARGET FOR REGULATION OF ALPHA-SYNUCLEIN EXPRESSION IN PRIMARY NEURONS IN VITRO 315
R. Mouridsen, M. Jakobsen, T.B. Hansen, J. Kjems (Aarhus, Denmark)
C027 ANALYSIS OF THE ROLE OF MICRORNAS IN AN ALPHA-SYNUCLEIN OVEREXPRESSION MOUSE MODEL 316
R. Petri, K. Pircs, M. Matusiak-Brueckner, J. Malmevik, J. Jakobsson (Lund, Sweden)
C028 PARKIN REGULATES KAINATE RECEPTORS CONTAINING THE GLUK2 SUBUNIT 317
G.M. Serratto, J. Sassone, M. Passafaro, A. Ciammola (Milano, Italy)
C029 GENE EXPRESSION CHANGES WITHIN THE HUMAN SUBTHALAMIC NUCLEUS DURING PARKINSON'S DISEASE 318
X.H. Wu, S. Reid, H. Waldvogel, R. Faull (Auckland, New Zealand)
 
EPOTHILONE-D RESCUES COGNITION AND ATTENUATES 
ALZHEIMER’S DISEASE-LIKE PATHOLOGY IN APP/PS1 MICE 
 
Fernandez-Valenzuela JJ.
1
, Sanchez-Varo R.
1
, De Castro V.
1
, Moyano FJ
2
, Vizuete M
2
, Davila JC
1
, 
Vitorica J.
2
 and Gutierrez A.
1 
 
1
Dept. Cell Biology, Genetics and Physiology, Faculty of Sciences, University of Malaga. IBIMA. 
CIBERNED.  Malaga, Spain. 
2
Dept. Biochemistry and Molecular Biology, Faculty of Pharmacy, University of Seville. IBIS. 
CIBERNED. Seville, Spain. 
 
AIMS: Cognitive decline in Alzheimer's disease (AD) patients has been linked to 
synaptic damage and neuronal loss. Hyperphosphorylation of tau protein destabilizes 
microtubules leading to the accumulation of autophagy/vesicular material and the 
generation of dystrophic neurites, thus contributing to axonal/synaptic dysfunction. In 
this study, we analyzed the effect of a microtubule-stabilizing compound in the 
progression of the disease in the hippocampus of APP751SL/PS1M146L transgenic model.  
METHODS: APP/PS1 mice (3 month-old) were treated with a weekly intraperitoneal 
injection of 2 mg/kg epothilone-D (Epo-D) for 3 months. Vehicle-injected animals were 
used as controls. Mice were tested on the Morris water maze, Y-maze and object-
recognition tasks for memory performance. Abeta, AT8, ubiquitin and synaptic markers 
levels were analyzed by Western-blots. Hippocampal plaque, synaptic and dystrophic 
loadings were quantified by image analysis after immunohistochemical stainings.   
RESULTS: Epo-D treated mice exhibited a significant improvement in the memory 
tests compared to controls. The rescue of cognitive deficits was associated to a 
significant reduction in the AD-like hippocampal pathology. Levels of Abeta, APP and 
ubiquitin were significantly reduced in treated animals. This was paralleled by a 
decrease in the amyloid burden, and more importantly, in the plaque-associated axonal 
dystrophy pathology. Finally, synaptic levels were significantly restored in treated 
animals compared to controls.  
CONCLUSION: Epo-D treatment promotes synaptic and spatial memory recovery, 
reduces the accumulation of extracellular Abeta and the associated neuritic pathology in 
the hippocampus of APP/PS1 model. Therefore, microtubule stabilizing drugs could be 
considered therapeutical candidates to slow down AD progression. 
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